Your AI-Trained Oncology Knowledge Connection!
Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the evolution of treatment for patients with HER2-positive metastatic breast cancer.
Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer.
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma.
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the results of the CARMENA study in patients with metastatic renal cell carcinoma.
Charles G. Drake, MD, PhD, discusses the importance of the CARMENA results, the future of cytoreductive nephrectomy, and how the use of immunotherapy could change treatment in this setting.
Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.
Owen O'Connor, MD, PhD, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma
Owen O'Connor, MD, PhD, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).
Columbia University and NewYork-Presbyterian announced today that Florence Irving and her late husband, Herbert Irving, have given $700 million to the two institutions to dramatically advance research and clinical programs for the treatment of cancer.
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.
Charles Drake, MD, PhD, discusses pairing immunotherapy with chemotherapy, the efficacy of current immunotherapy agents, and the future use of immunotherapy in the treatment of genitourinary cancers.
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the side effects associated with immunotherapy in genitourinary cancers.
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.
Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.
Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.
Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses the importance of developing accurate biomarkers when it comes to administering immunotherapy.
Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.
Today, in his laboratory at Columbia University, Murty Vundavalli, PhD continues working to understand the genetic and epigenetic aspects of cervical cancer in an attempt to elucidate prognostic markers of response to treatment.
Naiyer A. Rizvi, MD, discusses the future outlook for PD-1/PD-L1 checkpoint agents in non-small cell lung cancer and the potential for immunotherapy combinations.
Owen A. O'Connor, MD, PhD, professor of Medicine and Experiment Therapies, co-program director, Lymphoid Development and Malignancy Program, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses targeting CD30 expression in patients with diffuse large B-cell lymphoma.
Owen A. O'Connor, MD, PhD, discusses the evolving use of the anti-CD30 agent brentuximab vedotin across several lymphoma types.
Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.
Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.
Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).
Nicole Lamanna, MD, Associate Professor of Clinical Medicine, Columbia University Medical Center, discusses incorporating novel therapies into the standard treatment paradigm for patients with chronic lymphocytic leukemia (CLL).
Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses extensive biopsies in low-risk patients with prostate cancer.
Richard D. Carvajal, MD discusses the significance of researching, understanding, and improving outcomes for patients with rare cancers.
Richard D. Carvajal, MD, Director, Experimental Therapeutics and Melanoma Service New York-Presbyterian Hospital/ Columbia University Medical Center, discusses the challenge of using vaccines for cancer therapy.
A consensus has emerged among oncology practitioners that palliative care should not be seen as end-of-life care but is best deployed early to help patients and their caregivers manage symptoms throughout the cancer treatment trajectory.
Stephen G Emerson, MD, PhD, Clyde Wu Professor of Immunology and Medicine, director, Herbert Irving Comprehensive Cancer Center, explains the connection between stem cell mutations and leukemia.